The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis: A Chart Review Study

The purpose of this study is to investigate the value of Orencia in rapidly progressing Rheumatoid Arthritis (RA).

Inclusion Criteria:

• 18 years of age at enrollment
• Confirmed diagnosed with RA
• Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab with a record of the start date at the practice site

Exclusion Criteria:

• Does not have at least 1 or more poor RA prognostic factor: Evidence of joint erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP levels, Increased ESR levels
• Was followed at the site for less than 1 year since biologic treatment initiation
• Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, anal fistula

Other protocol defined inclusion/exclusion criteria could apply